Perceptive Advisors LLC Sells 40,000 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Perceptive Advisors LLC trimmed its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 39.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,800 shares of the medical equipment provider’s stock after selling 40,000 shares during the period. Perceptive Advisors LLC’s holdings in Intuitive Surgical were worth $27,492,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. One Wealth Management Investment & Advisory Services LLC grew its position in Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after acquiring an additional 23 shares during the period. Indiana Trust & Investment Management CO grew its position in Intuitive Surgical by 5.3% in the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 25 shares during the period. Hoxton Planning & Management LLC grew its position in Intuitive Surgical by 4.9% in the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after acquiring an additional 25 shares during the period. First Affirmative Financial Network grew its position in Intuitive Surgical by 2.7% in the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock valued at $443,000 after acquiring an additional 26 shares during the period. Finally, Moors & Cabot Inc. grew its position in Intuitive Surgical by 2.3% in the second quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock valued at $516,000 after acquiring an additional 26 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Trading Down 1.5 %

NASDAQ:ISRG opened at $479.18 on Monday. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $496.18. The business’s 50-day moving average price is $473.03 and its two-hundred day moving average price is $428.81. The firm has a market capitalization of $169.97 billion, a price-to-earnings ratio of 86.49, a PEG ratio of 5.39 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.18 earnings per share. Sell-side analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In other news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $446.60, for a total transaction of $167,921.60. Following the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,458,979.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the sale, the insider now owns 295 shares of the company’s stock, valued at approximately $145,113.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Robert Desantis sold 376 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $446.60, for a total value of $167,921.60. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,458,979.60. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock valued at $25,528,753 over the last 90 days. 0.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ISRG shares. Barclays boosted their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. Evercore ISI reduced their price objective on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research note on Friday, July 19th. Piper Sandler boosted their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Morgan Stanley boosted their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, JPMorgan Chase & Co. upped their price target on Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $446.45.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.